𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

✍ Scribed by Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti

Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
148 KB
Volume
5
Category
Article
ISSN
1776-2596

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The development of composite circulating
The development of composite circulating biomarker models for use in anticancer drug clinical development
✍ Lee J. Lancashire; Darren L. Roberts; Caroline Dive; Andrew G. Renehan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 373 KB

## Abstract The development of informative composite circulating biomarkers predicting cancer presence or therapy response is clinically attractive but optimal approaches to modeling are as yet unclear. This study investigated multidimensional relationships within an example panel of serum insulin‐

Clinical studies in the development of n
Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design
✍ Ferry A.L.M Eskens; Jaap Verweij 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Various new specifically targeted anticancer agents such as matrixmetalloproteinase inhibitors, angiogenesis inhibitors, farnesyl transferase inhibitors, and tyrosine kinase inhibitors have been developed in recent years. These agents exert antitumor activity through specific target inhibition, and